Tarsus Pharmaceuticals Inc. research snapshot
TARS AI stock analysis currently reads Tarsus Pharmaceuticals as a commercial-stage ophthalmic company that has rapidly grown revenue from $17 million in 2023 to an estimated $451 million in 2025 on the strength of its dry eye treatment TP-03 (varenicline). The analysis is not a certain price prediction. At the July 13, 2026 cutoff, the latest verified close used here was $58.14, market capitalization was about $2.50 billion, and the stock has declined 29% year-to-date from its $81.88 starting level. The core question was whether the recent sell-off creates a buying opportunity in a story that is still unprofitable, carries high short interest, and has an uncertain path to sustained profitability. This is informational research and not investment advice.
Current price
$58.14
Market cap
$2.50 billion
AI score
48 / 100
Rating
Transitional biotech with fast-growing revenue but not yet profitable
Trend status
Down from YTD highs, near 52-week low area
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Tarsus Pharmaceuticals is a commercial-stage ophthalmic company with a novel intranasal dry eye treatment (TP-03). Revenue grew from zero to $451 million in three years, demonstrating strong product-market fit. Gross margins above 93% reflect a high-value specialty pharma model. | Medium-high |
| Moat | The moat comes from its proprietary neuro-effector modulation platform, issued patents around varenicline formulations, first-to-market position in intranasal dry eye therapy, and established physician relationships. Switching costs are moderate. | Medium |
| Management | CEO Bobak Azamian and the leadership team have executed well on TP-03 launch and commercial scaling. Recent insider selling (CEO sold 10,000 shares in June) is a monitoring signal. The iRenix acquisition in July 2026 adds pipeline depth but also integration risk. | Medium |
| Financial trend | Revenue growth has been exceptional: $17M (2023) to $183M (2024) to $451M (2025). Net loss narrowed from -$136M to -$66M over the same period. Operating cash flow improved from -$117M to -$12M. The company has $389M in cash and short-term investments against $73M in long-term debt. | Medium-high |
| Valuation | The stock trades at approximately 5.5x trailing sales and 7.2x book value. P/E is not meaningful given negative TTM earnings of -$1.14 per share. The analyst consensus price target of $90.67 implies 56% upside, but the range spans $68 to $100, indicating wide uncertainty. | Low |
| Technical trend | TARS is down 29% YTD and trading near the lower end of its 52-week range ($38.51 to $85.25). The stock broke below its 50-day moving average and has been making lower highs. The area near $57 to $58 is being tested as support. | Medium |
| Risk level | Key risks: still unprofitable with uncertain timeline to GAAP profitability, high short interest at 15.15% of float, dependence on a single product (TP-03), competitive threat from other dry eye treatments, acquisition integration risk, and potential dilution if the company needs to raise capital. | Medium-high |
| AI confidence | Medium confidence for the business map and financial data due to available SEC filings and analyst coverage. Low confidence for the valuation framework because the company is not yet profitable and traditional P/E-based analysis is not applicable. | Medium |
| Investment certainty | Low certainty. Tarsus has a promising product and strong revenue growth, but the stock has sold off significantly in 2026, and the company still needs to demonstrate a clear path to sustained profitability. The high short interest adds further uncertainty. | Low |
TARS AI stock forecast
The TARS AI stock forecast uses scenario ranges around the $58.14 cutoff price. It does not claim that AI can predict a specific future price. The analyst consensus price target is $90.67, but forecasts are used as directional scenarios, not certain targets. The bullish case requires continued TP-03 market share gains, margin expansion, and pipeline progress. The base case assumes steady revenue growth but continued losses. The bearish case assumes competitive pressure, slower adoption, or capital raise concerns.
$92 to $105
More likely if TARS sustains 30%+ revenue growth, reaches operating breakeven within 12 months, successfully integrates iRenix/IRX-101, and the market re-rates the stock on a path to profitability. This aligns with the high end of analyst targets.
$68 to $85
More likely if revenue grows at 15% to 25%, losses continue to narrow but breakeven is 18 to 24 months away, and the stock trades in line with the analyst consensus area of $68 to $90.
$38 to $54
More likely if TP-03 faces market share erosion from competitors, the path to profitability extends beyond 24 months, integration challenges emerge from the iRenix acquisition, or the company needs to raise dilutive capital.
TARS AI technical analysis
TARS AI technical analysis starts from the $58.14 July 10 close used for this July 13 static page. Public technical sources showed the stock in a downtrend for 2026, trading near the lower half of its 52-week range. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $58.14 | Latest verified close used for this page as of the July 13, 2026 data cutoff. |
| Near resistance | $65.00 to $70.55 | The 50-day high area and a prior support-turned-resistance zone. A break above $70.55 would suggest the downtrend may be losing steam. |
| Near support | $55.00 to $57.41 | The 50-day low area. The stock tested this zone in recent trading. A hold here keeps the base-building possibility alive. |
| Secondary support | $38.51 | The 52-week low. A break below this level would represent a new low for the year and likely trigger further selling given the high short interest. |
| 50-day moving average | Approximately $62 to $66 | Estimated from the 50-day range of $57.41 to $70.55. The stock was trading below this level, which is a bearish near-term signal. |
| 200-day moving average | Approximately $55 to $62 | Estimated from the 52-week range and YTD price path. The stock was near this level, making it an important technical decision point. |
| Momentum | Weak downtrend, approaching oversold | The stock has declined 29% YTD with a series of lower highs since February 2026. A potential bullish divergence or base pattern would be needed to signal a reversal. |
| Volume | About 1.09 million shares (average) | The July 10 volume of 2.37 million was well above average, suggesting the recent decline attracted significant trading interest. |
| Volatility | Beta around 0.50 | The low beta suggests the stock does not move in tandem with the broader market. Price action is driven more by company-specific catalysts. |
| Invalidation | Close below $55, then $38.51 | A close below the $55 near-support area weakens the technical picture. A break below the $38.51 52-week low would represent a significant bearish development. |
TARS AI trading strategy
The TARS AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.
Given the current downtrend, a trend-following approach would wait for TARS to reclaim above the 50-day moving average (near $62 to $66) on above-average volume before considering a long position. The recent iRenix acquisition announcement is a catalyst to watch.
A daily close below $55 or a break below the 52-week low of $38.51 should invalidate the trend-following setup.
If TARS overshoots to the downside near the $55 support area and shows signs of stabilization (bullish divergence on RSI, volume drying up on sell-offs), a bounce trade toward the $65-$68 area could be considered. Given the high short interest, a squeeze is possible but not predictable.
Define maximum loss before entry. A close below $38.51 invalidates the mean-reversion thesis. Position size must account for the elevated short interest risk.
Track quarterly TP-03 prescription trends, revenue growth rate, operating expense trajectory, timeline to GAAP profitability, iRenix integration progress, competitive dynamics in dry eye market, and any secondary offering announcements.
Lower the rating if revenue growth decelerates below 15%, the company guides for extended losses, competitive pressure emerges from approved alternatives, or if insider selling accelerates.
Investment research summary
Tarsus Pharmaceuticals focuses on developing and commercializing novel therapies for eye diseases through neuro-effector modulation. Its lead product TP-03 (varenicline) is an intranasal spray for dry eye disease, offering a novel delivery mechanism for a condition affecting millions.
The moat derives from proprietary neuro-effector modulation technology, issued patents for varenicline-based ophthalmic treatments, first-mover advantage in intranasal dry eye therapy, established physician relationships and payer access, and high gross margins above 93% that reflect a differentiated product.
The thesis can fail if TP-03 faces stronger-than-expected competition from existing and emerging dry eye treatments, the path to profitability extends beyond 24 months requiring dilutive capital raises, the iRenix acquisition proves distracting or value-destructive, or if the high short interest reflects informed negative views about market opportunity or competitive positioning.
CEO Bobak Azamian leads a team with deep ophthalmic industry experience. Insider ownership at 9.64% provides moderate alignment, though the CEO sold 10,000 shares in June 2026. Management has demonstrated strong commercial execution in the TP-03 launch, but the iRenix acquisition adds execution complexity.
The dry eye disease market is large (estimated $5B+) and growing with an aging population and increasing screen time driving prevalence. Tarsus sits at the intersection of ophthalmology and novel drug delivery. The shift toward non-invasive, well-tolerated treatments favors TP-03, but competition from Restasis, Xiidra, Tyrvaya, and emerging alternatives is significant.
At roughly 5.5x trailing sales and $58.14, TARS is priced for continued growth but not yet for profitability. The stock trades 29% below its 2026 starting level and 32% below its 52-week high. The margin of safety depends on whether the market is correctly pricing the profitability timeline or over-discounting execution risk in an unprofitable growth story.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| TARS price | $58.14 close on July 10, 2026 | MarketBeat quote snapshot | July 13, 2026 |
| Market capitalization | $2.50 billion, verified as $58.14 x 43,020,000 shares | financial_rigor.py market cap verification and MarketBeat | July 13, 2026 |
| Revenue (2025) | $451.36 million | MarketBeat annual income statement | July 13, 2026 |
| Revenue growth rate | 147% YoY (2025 vs 2024) | MarketBeat annual income statement | July 13, 2026 |
| Net income (2025) | -$66.42 million, narrowing from -$116M in 2024 | MarketBeat annual income statement | July 13, 2026 |
| EPS (TTM) | -$1.14, P/E not meaningful | MarketBeat key statistics and financial_rigor.py | July 13, 2026 |
| Cash and short-term investments | $389 million as of Q1 2026 | MarketBeat quarterly balance sheet | July 13, 2026 |
| Long-term debt | $72.81 million | MarketBeat balance sheet | July 13, 2026 |
| Gross margin (2025) | 93.20% | MarketBeat metrics and ratios | July 13, 2026 |
| Insider ownership | 9.64% insider, 90.01% institutional | MarketBeat ownership data | July 13, 2026 |
| Short interest | 15.15% of float, 6.24 days to cover | MarketBeat short interest data | July 13, 2026 |
| Analyst consensus | Moderate Buy, price target $90.67 (range $68-$100) | MarketBeat analyst forecast | July 13, 2026 |
This TARS AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 13, 2026 and can be wrong. Tarsus Pharmaceuticals is an unprofitable biotech company with elevated execution risk.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
